(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 January 2010 (07.01.2010)

PCT

(10) International Publication Number
WO 2010/000565 A1

(51) **International Patent Classification**:
A61K 47/48 (2006.01) *C07K 16/22* (2006.01)
C07K 16/30 (2006.01)

(21) **International Application Number**:
PCT/EP2009/056976

(22) **International Filing Date**:
5 June 2009 (05.06.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
P200801652 8 June 2008 (08.06.2008) ES

(71) **Applicants** *(for all designated States except US)*: **FUNDACIÓ PRIVADA INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL HEBRON** [ES/ES]; Passeig Vall d'Hebron 119-129, Edifici de Recerca, E-08035 Barcelona (ES). **FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANCATS** [ES/ES]; Passeig Lluís Companys, 23, E-08010 Barcelona (ES). **FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON** [ES/ES]; Passeig Vall d'Hebron 119-129, Edifici matern-infantil, Planta 14, E-08035 Barcelona (ES).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **ARRIBAS LÓPEZ, Joaquín** [ES/ES]; Collserola, 83, E-08290 Cerdanyola del Vallés (ES). **PEDERSEN, Kim** [DK/ES]; Artesania, 126, 2° 2ª, E-08033 Barcelona (ES). **ANGELLINI, Pier-Davide** [IT/ES]; Tiro, 5-7, 7° 6ª, E-08035 Barcelona (ES). **PARRA PALAU, Josep Lluis** [ES/ES]; Passatge Garrofers, 15, 1° 1ª, E-08041 Barcelona (ES). **LAOS, Sirle** [EE/ES]; Muralla, 1. 3°, E-43830 Torredembarra (ES). **BASELGA TORRES, José** [ES/ES]; Vallmajor, 18-20, 4° 2ª, E-08021 Barcelona (ES).

(74) **Agents**: **SIEGERT, Georg** et al.; Hoffmann-Eitle, Arabellastrasse 4, 81925 München (DE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: METHOD FOR DIAGNOSING CANCERS EXPRESSING THE HER2 RECEPTOR OR ITS TRUNCATED VARIANTS

(57) **Abstract**: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognises an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ JD NO: 1 in a patient sample.

WO 2010/000565 A1